Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)

被引：0
|
作者：
Hughes, Derralynn [1 ]
Wilcox, William [2 ]
Hopkin, Robert J. [3 ]
Ganesh, Jaya [4 ]
Bernat, John [5 ]
Goker-Alpan, Ozlem [6 ]
Nicholls, Kathy [7 ]
Deegan, Patrick [8 ]
Pahl, Madeleine [9 ]
Whitley, Chester B. [10 ]
Chen, Michael
Cao, Liching
Schreeb, Katharina H.
机构：
[1] Royal Free London Hosp, London, England
[2] Emory Univ, Sch Med, Atlanta, GA USA
[3] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA
[4] Icahn Sch Med Mt Sinai, New York, NY USA
[5] Univ Iowa, Iowa City, IA USA
[6] Lysosomal & Rare Disorders Res & Treatment Ctr, Fairfax, VA USA
[7] Addenbrookes Hosp, Cambridge, England
[8] Univ Calif Irvine, Irvine, CA USA
[9] Univ Minnesota, Minneapolis, MN USA
[10] Sangamo Therapeut Inc, Richmond, CA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2025年 / 144卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2024.108773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
146
引用
收藏
页数：2
相关论文
共 50 条
  • [31] LENTIGLOBIN GENE THERAPY FOR PATIENTS WITH SICKLE CELL DISEASE: UPDATED RESULTS FROM STUDY HGB-206
    Thompson, Alexis
    Krishnamurti, Lakshmanan
    Mapara, Markus
    Kwiatkowski, Janet
    Tisdale, John
    Schmidt, Manfred
    Miller, Alexandra
    Pierciey, Francis, Jr.
    Huang, Wenmei
    Ribeil, Jean-Antoine
    Kanter, Julie
    Walters, Mark
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S32 - S32
  • [32] AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease: Overview of clinical data from phase 1 and phase 2 studies
    Thomas, Mark
    Nicholls, Kathleen
    Carnley, Benedict
    Trame, Mirjam
    Mason, Chris
    Tavakkoli, Fatemeh
    Keenan, Greg
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S106 - S106
  • [33] Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a
    Leavitt, Andrew D.
    Konkle, Barbara A.
    Stine, Kimo
    Visweshwar, Nathan
    Harrington, Thomas J.
    Giermasz, Adam
    Arkin, Steven
    Fang, Annie
    Plonski, Frank
    Smith, Lynne
    Tseng, Li-Jung
    Di Russo, Gregory
    Cockroft, Bettina M.
    Rupon, Jeremy
    Rouy, Didier
    BLOOD, 2020, 136
  • [34] Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).
    Milhem, Mohammed M.
    Vanderwalde, Ari M.
    Bowles, Tawnya Lynn
    Sacco, Joseph J.
    Niu, Jiaxin
    Tsai, Katy K.
    Chesney, Jason Alan
    Chmielowski, Bartosz
    Samson, Adel
    Rhodes, Terence Duane
    In, Gino Kim
    Pavlick, Anna C.
    Wise-Draper, Trisha Michel
    Sanmamed, Miguel F.
    Bommareddy, Praveen
    Zhu, Junhong
    Coffin, Robert S.
    Harrington, Kevin Joseph
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] AAV8 gene therapy as a potential treatment for adults with late-onset ornithine transcarbamylase (OTC) deficiency: updated results from a phase 1/2 clinical trial
    Geberhiwot, T.
    Couce, M. L.
    Hualde, L. C.
    Harding, C. O.
    Khan, A.
    Diaz, G. A.
    Tan, W.
    Konczal, L.
    Thomas, J.
    Guffon, N.
    Lee, C.
    Puga, A. C.
    Crombez, E.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A9 - A9
  • [36] AAV8 Gene Therapy as a Potential Treatment in Adults with Late-Onset Ornithine Transcarbamylase (OTC) Deficiency: Updated Results from a Phase 1/2 Clinical Trial
    Harding, Cary O.
    Luz Couce, Maria
    Geberhiwot, Tarekegn
    Tan, Wen-Hann
    Khan, Aneal
    Aldamiz-Echevarria, Luis
    Diaz, George A.
    Lee, Connie
    Puga, Ana Cristina
    Crombez, Eric
    MOLECULAR THERAPY, 2021, 29 (04) : 17 - 17
  • [37] EFFICACY AND SAFETY OF LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA AND NON-β0/β0 GENOTYPES: UPDATED RESULTS FROM THE COMPLETED PHASE 1/2 NORTHSTAR AND ONGOING PHASE 3 NORTHSTAR-2 STUDIES
    Rasko, J.
    Walters, M.
    Kwiatkowski, J.
    Hongeng, S.
    Porter, J.
    Sauer, M.
    Thrasher, A.
    Thuret, I.
    Schiller, G.
    Elliot, H.
    Deary, B.
    Chen, Y.
    Tao, G.
    Asmal, M.
    Locatelli, F.
    Thompson, A.
    CYTOTHERAPY, 2019, 21 (05) : S14 - S14
  • [38] Efficacy and safety of LentiGlobin gene therapy in patients with transfusion-dependent β-thalassaemia and non-β0/β0 genotypes: Updated results from the completed phase 1/2 Northstar and ongoing phase 3 Northstar-2 studies
    Porter, J. B.
    Walters, M. C.
    Kwiatkowski, J. L.
    Hongeng, S.
    Rasko, J. E. J.
    Sauer, M. G.
    Thrasher, A. J.
    Thuret, I.
    Schiller, G. J.
    Elliot, H.
    Deary, B.
    Chen, Y.
    Tao, G.
    Asmal, M.
    Locatelli, F.
    Thompson, A. A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 23 - 23
  • [39] UPDATED RESULTS FROM THE HGB-206 GROUP C STUDY OF LENTIGLOBIN FOR SICKLE CELL DISEASE GENE THERAPY
    Kwiatkowski, Janet
    Thompson, Alexis
    Walters, Mark
    Mapara, Markus
    Krishnamurti, Lakshmanan
    Aygun, Banu
    Kasow, Kimberly
    Rifkin-Zenenberg, Stacey
    Schmidt, Manfred
    Miller, Alex
    Gallagher, Meghan
    Chen, Ren
    Kim, Dennis
    Goyal, Sunita
    Kanter, Julie
    Tisdale, John
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S2 - S3
  • [40] Resolution of Serious Vaso-occlusive Pain Crises: Results From The Ongoing Phase 1/2 HGB-206 Group C Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
    Mapara, Markus
    Walters, Mark
    Thompson, Alexis
    Kwiatkowski, Janet
    Krishnamurti, Lakshmanan
    Aygun, Banu
    Kasow, Kimberly
    Rifkin-Zenenberg, Stacey
    Schmidt, Manfred
    Nnamani, Mauris
    VanNest, Sara
    Pierciey, Francis, Jr.
    Miller, Alex
    Chen, Ren
    Kim, Dennis
    Goyal, Sunita
    Kanter, Julie
    Tisdale, John
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 66 - 68
12345